Clinical trial
A Phase II Study of Maintenance With Azacitidine in MDS Patients
NCT00446303 · Groupe Francophone des Myelodysplasies, Other · Terminated
Key facts
| NCT number | NCT00446303 |
|---|---|
| Title | A Phase II Study of Maintenance With Azacitidine in MDS Patients |
| Official title | A Phase II Study of Maintenance With Azacitidine in MDS Patients Achieving Complete or Partial Remission (CR or PR) After Intensive Chemotherapy |
| Lead sponsor | Groupe Francophone des Myelodysplasies, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelocytic, Acute, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Azacitidine |
| Enrollment | 39 |
| Start date | Jul 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Mar 12, 2007 |
| Last update posted | Jan 19, 2012 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: